Insights

More Articles Back to Article

Daewoong to advance Phase 1 study for COVID-19 drug

Daewoong Pharmaceutical of South Korea has gained regulatory approval to advance an early-stage trial for niclosamide, its anti-parasitic drug, to treat patients with COVID-19 infections. The company is aiming for conditional approval of DWRX2003, an antiviral drug, for emergency use after results become available from a midstage trial. Reuters (10/12)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!